Recent Updates
Recently added Catalysts

tanezumab

Phase 3

Arthritis | Monoclonal antibody | Musculoskeletal |Pfizer, Inc.|Trials Updated: Feb 16, 2023

tanezumab development status

Highest phase Phase 3
Registered trials 18 across 1 sponsor since Jan 2008

tanezumab target and mechanism

Molecular targetNGF
Target classInhibitor
ModalityMonoclonal antibody

Also known as PF-04383119

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials15
Total Enrollment8,416

FDA Designations

No designations recorded

tanezumab clinical trials

tanezumab · 15 trials · 14 indications

Phase 3 8Phase 2 6Phase 1 1
NCT02709486Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.Osteoarthritis, Hip
COMPLETED849 Analytics
NCT02697773Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or KneeOsteoarthritis, Knee
COMPLETED698 Analytics
NCT02609828Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyBone Metastasis
COMPLETED156 Analytics
NCT02528253A Phase 3 Study of Tanezumab for Chronic Low Back PainLow Back Pain
COMPLETED1,832 Analytics
NCT00863304Tanezumab in Osteoarthritis of the Hip or Knee (2)Osteoarthritis
COMPLETED849 Analytics
NCT00830063Tanezumab In Osteoarthritis Of The Knee (2)Arthritis
COMPLETED832 Analytics
NCT00744471Tanezumab in Osteoarthritis Of The HipArthritis
COMPLETED627 Analytics
NCT00733902Tanezumab in Osteoarthritis of the KneeArthritis
COMPLETED697 Analytics
PHASE3COMPLETED
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
Osteoarthritis, HipUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
Osteoarthritis, KneeUnlock trial analytics
PHASE3COMPLETED
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Bone MetastasisUnlock trial analytics
PHASE3COMPLETED
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
Low Back PainUnlock trial analytics
PHASE3COMPLETED
Tanezumab in Osteoarthritis of the Hip or Knee (2)
OsteoarthritisUnlock trial analytics
PHASE3COMPLETED
Tanezumab In Osteoarthritis Of The Knee (2)
ArthritisUnlock trial analytics
PHASE3COMPLETED
Tanezumab in Osteoarthritis Of The Hip
ArthritisUnlock trial analytics
PHASE3COMPLETED
Tanezumab in Osteoarthritis of the Knee
ArthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24
Baseline, Week 24

WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24
Baseline, Week 24

WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function.

Change From Baseline in the Patient's Global Assessment (PGA) of Osteoarthritis at Week 24
Baseline, Week 24

PGA of OA was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16
Baseline, Week 16

WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16
Baseline, Week 16

WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function.

Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis at Week 16
Baseline, Week 16

PGA of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

Change From Baseline in the Daily Average Pain Intensity Numerical Rating Score (NRS) in the Index Bone Metastasis Cancer Pain Site at Week 8
Baseline, Week 8

Daily average pain intensity in the index bone metastasis cancer pain site was assessed by participants on an 11 point pain intensity NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores signified more severity of pain. The participants recorded their daily average pain at the painful site during the past 24 hours by choosing the appropriate number from 0 to 10 on interactive response technology (IRT) diaries. Baseline daily average pain intensity value was mean of the daily average pain intensity NRS scores during the baseline assessment period prior to randomization. Baseline assessment period was up to 5 days prior to dosing. The Week 8 daily average pain intensity value was the mean of the daily average pain intensity NRS scores recorded for each of the 7 days prior to the Week 8.

Change From Baseline in Average Low Back Pain Intensity (LBPI) Score for Tanezumab Versus (Vs) Placebo at Week 16
Baseline, Week 16

Average low back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive response technology (IRT). Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated maximum difficulty. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function.

Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

PGA of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.

Change From Baseline in Patient Global Assessment of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

Participants answered: "Considering all the ways the osteoarthritis in your index knee affects you, how are you doing today?" Participants responded on the scale ranging from 1 (minimum affected) to 5 (maximum affected), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicate worse condition.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline (Day 1), Week 16

WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 16: Baseline Observation Carried Forward (BOCF)
Baseline, Week 16

Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Overall possible score range for daily average LBPI at specified visit was 0= no pain to 10= worst possible pain, where higher scores indicated higher pain intensity.

Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Week 6
Baseline, Week 6

Daily average pain was assessed on an 11-point NRS over the past 24 hours (before each specified visit), where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". Lower the score, lesser the pain intensity.

Change From Baseline in Average Daily Pain Score at Week 6
Baseline, Week 6

Participants assessed average chronic prostatitis pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no chronic prostatitis pain) to 10 (chronic prostatitis pain as bad as you can imagine). The average daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain.

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Day 1 up to Day 92 for tanezumab 10, 25, 50 mcg/kg group and matching placebo group (Part 1, 2); Day 1 up to Day 120 for tanezumab 100 mcg/kg group and matching placebo group (Part 1, 2), 200 mcg/kg group and matching placebo group (Part 1)

An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent: events between first dose of study drug and up to Day 1 through Day 120 (Part 1 and 2) were absent before treatment or that worsened relative to pretreatment state

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Baseline
Baseline (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Day 1
Day 1 (Part 1 and 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Day 4/5
Day 4/5 (Part 1 and 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 1
Week 1 (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 2
Week 2 (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 3
Week 3 (Part 1 and 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 4
Week 4 (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 13
Week 13 (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score at Week 17
Week 17 (Part 1 and Part 2)

The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the participant's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). Higher score indicated best memory.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 1
Baseline, Week 1 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 2
Baseline, Week 2 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 3
Baseline, Week 3 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 4
Baseline, Week 4 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 5
Baseline, Week 5 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline In Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 6
Baseline, Week 6 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline In Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 7
Baseline, Week 7 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 10 0= extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline In Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 8
Baseline, Week 8 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 9
Baseline, Week 9 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 10
Baseline, Week 10 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 11
Baseline, Week 11 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 12
Baseline, Week 12 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Current Index Knee Pain at Week 13
Baseline, Week 13 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for current index knee pain was recorded on the electronic diary.

Change From Baseline Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 1
Baseline, Week 1 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 2
Baseline, Week 2 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 3
Baseline, Week 3 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 4
Baseline, Week 4 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in The Past 24 Hours at Week 5
Baseline, Week 5 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 6
Baseline, Week 6 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 7
Baseline, Week 7 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 8
Baseline, Week 8 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 9
Baseline, Week 9 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 10
Baseline, Week 10 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 11
Baseline, Week 11 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 12
Baseline, Week 12 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain in the Past 24 Hours at Week 13
Baseline, Week 13 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 1
Baseline, Week 1 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 2
Baseline, Week 2 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 3
Baseline, Week 3 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 4
Baseline, Week 4 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 5
Baseline, Week 5 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 6
Baseline, Week 6 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 7
Baseline, Week 7 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 8
Baseline, Week 8 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 9
Baseline, Week 9 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 10
Baseline, Week 10 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 11
Baseline, Week 11 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 12
Baseline, Week 12 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Visual Analogue Scale (VAS) Score For Index Knee Pain During Walking in the Past 24 Hours at Week 13
Baseline, Week 13 (Part 1 and 2)

VAS assesses participant responses from 0 to 100 (0 = none to 100 = extreme) with 101 point resolution for measuring pain intensity. Higher score indicated greater pain intensity. VAS for index knee pain during walking in the past 24 hours was recorded on the electronic diary.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Version 3.1 (WOMAC 3.1) Subscales Scores at Week 1
Baseline, Week 1 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0 = none to 100 = extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in WOMAC 3.1 Subscales Scores at Week 2
Baseline, Week 2 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0 = none to 100 = extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in WOMAC 3.1 Subscales Scores at Week 4
Baseline, Week 4 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0 = none to 100 = extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in WOMAC 3.1 Subscales Scores at Week 8
Baseline, Week 8 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0=none to 100= extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in WOMAC 3.1 Subscales Scores at Week 13
Baseline, Week 13 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0 = none to 100 = extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in WOMAC 3.1 Subscales Scores at Week 17
Baseline, Week 17 (Part 1 and 2)

WOMAC 3.1: participant assessed questionnaire consists of 24 questions divided into 3 domains; pain (5 questions), stiffness (2 questions), function (17 questions). Functional domain provided information of ability to perform activities of daily living. The participant performed test directly on electronic diary, using validated electronic VAS ranging from 0 to 100 (0 = none to 100 = extreme). Each domain scored by averaging VAS scores of component questions. Total subscale score for each of the 3 domains range from: 0 to 100, lower score indicated better daily living.

Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 6
Baseline, Week 6

Daily average low back pain was assessed on an 11-point numeric rating scale (NRS). Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5-day prior to randomization (initial pain assessment period). Post-baseline weekly scores were calculated based on the mean of the scores over the 7 days prior to and including the day at the end of the corresponding week.

To assess the change in intraepidermal nerve fiber (IENF) density in skin biopsies from proximal thigh and distal leg between baseline and postdose time points after a single SC injection of tanezumab 20 mg SC or placebo in healthy volunteers.
16 weeks
To compare the treatment effect between tanezumab 20 mg SC and placebo on the change in IENF density between baseline and postdose time points in skin biopsies from the proximal thigh and distal leg in healthy volunteers.
16 weeks
To assess the safety, tolerability and immunogenicity of a single dose of tanezumab 20 mg SC in healthy volunteers.
16 weeks

Secondary Endpoints

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 2, 4, 8, 12 and 16
Baseline, Weeks 2, 4, 8, 12 and 16
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 32
Baseline, Week 32
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8, 12 and 16
Baseline, Weeks 2, 4, 8, 12 and 16
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Low doseEXPERIMENTALInvestigational product
High doseEXPERIMENTALInvestigational product
PlaceboPLACEBO_COMPARATORInvestigational product
Tanezumab 2.5 mgEXPERIMENTALtanezumab 2.5 mg administered subcutaneously at day 0 and week 8
Tanezumab 2.5mg/5mgEXPERIMENTALtanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
Arm 1EXPERIMENTALTanezumab 20 mg subcutaneously
Arm 2PLACEBO_COMPARATORPlacebo matched to active treatment subcutaneously
Placebo to Week 16; tanezumab 5 mg SCPLACEBO_COMPARATOR -
Placebo to Week 16, tanezumab 10 mg SCPLACEBO_COMPARATOR -
Tanezumab 5 mg SCEXPERIMENTAL -
Tanezumab 10 mg SCEXPERIMENTAL -
Tramadol PR oralACTIVE_COMPARATOR -
1EXPERIMENTAL -
2EXPERIMENTAL -
3ACTIVE_COMPARATOR -
4PLACEBO_COMPARATOR -
Tanezumab 10 mgEXPERIMENTALTanezumab 10 mg IV every 8 weeks
Tanezumab 5 mgEXPERIMENTALTanezumab 5mg IV every 8 weeks
Tanezumab 20 mg IVEXPERIMENTAL -
Tanezumab 10 mg IVEXPERIMENTAL -
Tanezumab 5 mg IVEXPERIMENTAL -
NaproxenACTIVE_COMPARATOR -
Tanezumab 10 mg IV + opioidsEXPERIMENTAL -
Placebo + opioidsPLACEBO_COMPARATORSingle IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
TanezumabEXPERIMENTAL -
10 mcg/kgEXPERIMENTAL -
100 mcg/kgEXPERIMENTAL -
200 mcg/kgEXPERIMENTAL -
25 mcg/kgEXPERIMENTAL -
50 mcg/kgEXPERIMENTAL -
RN624EXPERIMENTAL -

Interventions

NameTypeDescription
TanezumabDRUG2.5 mg
PlaceboDRUGPlacebo
Tanezumab 2.5 mgBIOLOGICALPatient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
Tanezumab 2.5mg/5mgBIOLOGICALPatient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
Placebo to Week 16; tanezumab 5mg SCBIOLOGICALPlacebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
Placebo to Week 16, tanezumab 10 mg SCBIOLOGICALPlacebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
Tanezumab 5 mg SCBIOLOGICALTanezumab 5 mg SC
Tanezumab 10 mg SCBIOLOGICALTanezumab 10 mg SC
Tramadol PR oralBIOLOGICALTramadol PR oral
tanezumab 10 mgBIOLOGICALtanezumab 10 mg one dose at weeks 0 and 8
tanezumab 5 mgBIOLOGICALtanezumab 5 mg one dose at weeks 0 and 8
naproxenDRUGnaproxen 1000 mg daily for 16 weeks
Tanezumab 20 mg IVBIOLOGICAL2 IV administrations of tanezumab 20 mg at an 8 week interval
Placebo for naproxenDRUGOral placebo for naproxen twice a day for 16 weeks
Tanezumab 10 mg IVBIOLOGICAL2 IV administrations of tanezumab 10 mg at an 8 week interval
Tanezumab 5 mg IVBIOLOGICAL2 IV administrations of tanezumab 5 mg at an 8 week interval
Placebo for tanezumabBIOLOGICAL2 IV administrations of placebo for tanezumab at an 8 week interval
IV Placebo for tanezumabDRUGSingle IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
PF-04383119 (tanezumab)DRUGsingle dose of 10 mcg/kg IV
PF-04383119DRUGPF-04383119 200 mcg/kg IV, single dose
PF-04383119 (RN624)DRUGSingle IV infusion of 200 micrograms/kg RN624 on Day 1
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites148

Inclusion Criteria: * A diagnosis of osteoarthritis of the index hip or knee based on American College of Rheumatology criteria with Kellgren Lawrence x-ray Grade of at least 2 as diagnosed by the Central Reader * A history of insufficient pain relief from acetaminophen along with a history of insu...

Countries:AustriaBulgariaFinlandFranceGermanyHungaryItalyJapanPolandPortugalRomaniaSlovakiaSpainSwedenUnited KingdomUnited StatesCanadaPuerto RicoArgentinaAustraliaBrazilChileChinaCzechiaIsraelSouth KoreaDenmarkBosnia and HerzegovinaCroatiaIndiaLatviaMexicoPeruSwitzerland
Unlock Eligibility Criteria

Competitive Landscape -Arthritis 9 trials

No competing companies are currently tracked in active development for Arthritis.
Unlock Competitive Intelligence

Frequently asked questions about tanezumab

What is tanezumab?

Tanezumab is an investigational monoclonal antibody developed by Pfizer, Inc. (NYSE: PFE) for the treatment of pain. It has been studied in Phase 3 clinical trials for osteoarthritis of the hip or knee, chronic low back pain, and cancer pain due to bone metastasis. It is not approved and remains in clinical development.

What does tanezumab target?

Tanezumab targets nerve growth factor, or NGF, and acts as an inhibitor of this target. By binding NGF, the antibody is designed to interfere with NGF signaling associated with pain. This mechanism underlies its study as an analgesic in conditions such as osteoarthritis and chronic low back pain.

Who makes tanezumab?

Tanezumab is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the Phase 3 clinical program evaluating tanezumab across osteoarthritis, chronic low back pain, and cancer pain due to bone metastasis.

What phase is tanezumab in?

Tanezumab is in Phase 3 clinical development and is investigational. It has not been approved by the FDA. The Phase 3 program includes completed trials in osteoarthritis of the hip or knee, chronic low back pain, and cancer pain due to bone metastasis, with a total of 3,191 enrolled participants across the studies.

What clinical trials is tanezumab in?

Tanezumab has been evaluated in completed Phase 3 trials including NCT02709486 in hip or knee osteoarthritis, NCT02697773 in moderate to severe hip or knee osteoarthritis, NCT02528253 in chronic low back pain, and NCT02609828 in cancer pain due to bone metastasis. All were randomized, double-blind, controlled studies.